文献速递白血病

前瞻性VenEx试验中体外维奈克拉敏感性可预测急性髓系白血病的临床反应

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.
PubMed 文献 · Blood · 2025-01-01

这项前瞻性、多中心、2期试验纳入104例初治、复发/难治或既往治疗过的继发性急性髓系白血病患者,评估体外维奈克拉敏感性预测维奈克拉-阿扎胞苷疗效的价值。104例中102例成功评估敏感性,中位3天出结果;初治敏感者完全缓解/完全缓解伴血液学不完全恢复率为85%,总生存28.7个月,耐药者仅5.5个月;复发/难治/继发性患者敏感者缓解率62%,总生存9.7个月对3.3个月。

要点

  • 初治AML体外敏感者CR/CRi率85%(34/40),中位OS 28.7个月,耐药者5.5个月(P=.002)。
  • 复发/难治/继发AML敏感者CR/CRi率62%(21/34),中位OS 9.7个月对3.3个月(P<.001)。
  • 多因素分析显示体外维奈克拉敏感性是治疗反应和生存的最强预测因素。

核心结论

  • 本试验表明将体外药物检测整合入临床实践以识别可从维奈克拉获益的AML患者是可行的,尤其在复发/难治情况下。

研究设计与样本

  • 前瞻性、多中心、2期试验,纳入104例急性髓系白血病患者,其中初治48例、复发/难治39例、既往治疗过的继发性17例。
  • 主要终点为体外敏感受试者前3个治疗周期内完全缓解或完全缓解伴血液学不完全恢复(CR/CRi)率。
  • 关键次要终点包括体外药物敏感性与治疗反应及生存的相关性。
  • 试验注册号NCT04267081。

主要发现

  • 104例中102例成功评估维奈克拉敏感性,自采样至结果可用的中位时间为3天。
  • 初治AML中,体外敏感者CR/CRi率85%(34/40),中位总生存28.7个月;体外耐药者中位总生存5.5个月(P=.002)。
  • 复发/难治/继发性AML中,体外敏感者CR/CRi率62%(21/34),中位总生存9.7个月;体外耐药者中位总生存3.3个月(P<.001)。
  • 单因素和多因素分析中,体外维奈克拉敏感性是良好治疗反应和生存的最强预测因素。

临床怎么用

  • 作者认为将体外药物检测整合入临床实践以识别可从维奈克拉获益的AML患者是可行的,尤其在复发/难治情况下。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The B-cell lymphoma 2 inhibitor venetoclax has shown promise for treating acute myeloid leukemia (AML). However, identifying patients likely to respond remains a challenge, especially for those with relapsed/refractory (R/R) disease. We evaluated the utility of ex vivo venetoclax sensitivity testing to predict treatment responses to venetoclax-azacitidine in a prospective, multicenter, phase 2 trial. The trial recruited 104 participants with previously untreated (n = 48), R/R (n = 39), or previously treated secondary AML (sAML) (n = 17). The primary end point was complete remission or complete remission with incomplete hematologic recovery (CR/CRi) rate in ex vivo sensitive trial participants during the first 3 therapy cycles. The key secondary end points included the correlations between ex vivo drug sensitivity, responses, and survival. Venetoclax sensitivity was successfully assessed in 102 of 104 participants, with results available within a median of 3 days from sampling. In previously untreated AML, ex vivo sensitivity corresponded to an 85% (34/40) CR/CRi rate, with a median overall survival (OS) of 28.7 months, compared with 5.5 months for ex vivo resistant patients (P = .002). For R/R/sAML, ex vivo sensitivity resulted in a 62% CR/CRi rate (21/34) and median OS of 9.7 vs 3.3 months for ex vivo resistant patients (P < .001). In univariate and multivariate analysis, ex vivo venetoclax sensitivity was the strongest predictor for a favorable treatment response and survival. This trial demonstrates the feasibility of integrating ex vivo drug testing into clinical practice to identify patients with AML, particularly in the R/R setting, who benefit from venetoclax. This trial was registered at www.clinicaltrials.gov as #NCT04267081.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kytölä S, Vänttinen I, Ruokoranta T, et al. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial. Blood. 2025. PMID: 39357056. doi:10.1182/blood.2024024968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。